Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
The bill strengthens FDA notification and follow-up requirements when finished infant formula tests positive for microorganisms. It shortens notification timelines, requires manufacturers to share isolates or whole genetic sequences, and mandates FDA engagement and confirmation of corrective actions.
Left emphasizes stronger oversight and public safety benefits
Relative to its intended legislative type, this bill amends existing statutory authority to create specific manufacturer notification duties and imposes an extensive reporting and oversight regime on the Secretary.
The bill strengthens FDA notification and follow-up requirements when finished infant formula tests positive for microorganisms.
It shortens notification timelines, requires manufacturers to share isolates or whole genetic sequences, and mandates FDA engagement and confirmation of corrective actions.
The bill also requires a 180-day progress report on prior FDA recommendations, quarterly supply-chain reporting for five years, interagency consultation, and 1-, 3-, and 5-year stakeholder reports on supply adequacy and evidence-based practices.
Low-salience, technical safety improvements with limited fiscal impact increase chances, but industry compliance concerns and absence of funding language create uncertainty.
Relative to its intended legislative type, this bill amends existing statutory authority to create specific manufacturer notification duties and imposes an extensive reporting and oversight regime on the Secretary. It integrates cleanly into the Federal Food, Drug, and Cosmetic Act and establishes clear timelines and roles.
Left emphasizes stronger oversight and public safety benefits
These are examples from the analysis, not a ranked list of the most-affected groups.
Left emphasizes stronger oversight and public safety benefits
Overall supportive: the bill increases oversight, transparency, and preventive action to protect infants from contaminated formula.
It also directs the FDA to track supply resiliency and pursue evidence-based improvements.
It may be seen as a needed regulatory strengthening, though advocates may press for clearer public disclosure and stronger enforcement tools.
Generally favorable but pragmatic: the bill targets infant safety and supply stability with clear timelines.
Concerns center on FDA capacity, costs for manufacturers, and avoiding unintended supply disruptions.
Support contingent on resourcing and measured implementation.
Skeptical: while infant safety is a priority, this bill increases federal oversight and rapid intervention authority.
It may impose burdens on manufacturers and risk supply disruptions.
Concerns include federal overreach, proprietary data sharing, and cost impacts.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Low-salience, technical safety improvements with limited fiscal impact increase chances, but industry compliance concerns and absence of funding language create uncertainty.
The bill has not accumulated any surfaced votes yet.
Left emphasizes stronger oversight and public safety benefits
Low-salience, technical safety improvements with limited fiscal impact increase chances, but industry compliance concerns and absence of fu…
Relative to its intended legislative type, this bill amends existing statutory authority to create specific manufacturer notification duties and imposes an extensive reporting and oversight regime on the Secretary. It i…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.